HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

Benzinga Newsdesk www.benzinga.com Positive 70.9%

Neg 0% Neu 0% Pos 70.9%

HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.